A phase I study of nintedanib combined with cisplatin/gemcitabine as first-line therapy for advanced squamous non-small cell lung cancer (LUME-Lung 3).
Name:
PIIS0169500218302976.pdf
Size:
363.3Kb
Format:
PDF
Description:
Full text, Open Access article
Authors
Forster, MHackshaw, A
De Pas, T
Cobo, M
Garrido, P
Summers, Yvonne J
Dingemans, A
Flynn, M
Schnell, D
von Wangenheim, U
Loembé, A
Kaiser, R
Lee, S
Affiliation
Department of Oncology, University College London Cancer Institute, London, UKIssue Date
2018-06
Metadata
Show full item recordAbstract
There are limited treatment options for squamous non-small cell lung cancer (sqNSCLC) and prognosis remains poor. The safety and pharmacokinetics (PK) of nintedanib, a triple angiokinase inhibitor, plus cisplatin/gemcitabine as first-line treatment for advanced sqNSCLC patients, were evaluated.Citation
A phase I study of nintedanib combined with cisplatin/gemcitabine as first-line therapy for advanced squamous non-small cell lung cancer (LUME-Lung 3). 2018, 120: 27-33 Lung CancerJournal
Lung CancerDOI
10.1016/j.lungcan.2018.03.007PubMed ID
29748012Type
ArticleLanguage
enISSN
1872-8332ae974a485f413a2113503eed53cd6c53
10.1016/j.lungcan.2018.03.007